E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma

Abstract

Cis-diamminodichloroplatinum (II) (cis-DDP), 100 mg/m2 every 3 weeks was administered to 24 patients with advanced soft tissue sarcoma. All patients had received extensive prior chemotherapy and had measurable progressive disease and normal renal function on entry to the study. There were no objective responses in the 17 patients receiving an adequate trial of therapy. Nausea and vomiting were universal. Renal impairment was moderate in 2 patients and mild in 4. Serial audiometry detected hearing loss at high frequencies in 3 patients.